should a second generation alk inhibitor be first line therapy for patients with alk-positive nsclc?
Published 8 years ago • 68 plays • Length 4:14Download video MP4
Download video MP3
Similar videos
-
2:20
timing of second generation alk inhibitors: first line vs. treatment after acquired resistance
-
2:00
ceritinib and other second generation alk inhibitors for acquired resistance in alk-positive nsclc
-
22:10
first and second generation alk inhibitors for the treatment of lung cancer
-
3:44
alk inhibitors for acquired resistance: zykadia and alectinib
-
26:56
gracecast-085_lung-cancer_alk inhibition: who to screen and options for alk-positive patients
-
4:44
are there clinically significant differences among the second generation alk inhibitors?
-
4:58
how do the new alk inhibitor drugs compare to xalkori (crizotinib) for alk lung cancer patients?
-
0:45
slcvl - hunis - #12 second line therapy for nsclc and alk
-
19:47
alk positive forum next generation inhibitors
-
37:41
gracecast-044_lung-cancer_camidge on alk inhibitors
-
6:29
case based panel discussion nsclc – does a positive her2 mutation effect treatment decisions?
-
5:42
gracecast - lcvl- what are the options after a patient with an alk-positive advanced nsclc develops
-
1:47
alk rearrangements: what are they, and who has them?
-
1:57
alk nsclc: what does it mean? - 2022 program: targeted therapies forum
-
3:06
2020 ttf alk session qa panel progression on 2nd-gen alk inhibitor if biopsy shows no alk mutation
-
9:59
case based panel discussions - alk positive, developing resistance to alk inhibitors and next steps
-
21:58
grace targeted therapies lung cancer 2021 - alk therapies-which one comes first, how do we sequence?
-
6:49
can we improve on xalkori? new agents for patients with an alk-1 rearrangement
-
33:47
gracecast-049_lung-cancer_weiss on egfr therapy for early stage nsclc